New York State Common Retirement Fund Alaunos Therapeutics, Inc. Transaction History

New York State Common Retirement Fund

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 04, 2022	SELL	$0.41 - $1.24 $55,880 - $169,005	-136,295 Reduced 98.8%	1,650 $2,000
Q4 2021 Feb 02, 2022	SELL	$1.09 - $1.89 $297 - $515	-273 Reduced 0.2%	137,945 $150,000
Q3 2021 Nov 02, 2021	SELL	$1.44 - $2.73 $56,257 - $106,655	-39,068 Reduced 22.04%	138,218 $252,000
Q2 2021 Aug 02, 2021	BUY	$2.63 - $3.67 $4,697 - $6,554	1,786 Added 1.02%	177,286 $468,000
Q1 2021 May 11, 2021	BUY	$2.82 - $5.6 $42,864 - $85,120	15,200 Added 9.48%	175,500 $632,000
Q4 2020 Feb 08, 2021	SELL	$2.09 - $3.09 $72,941 - $107,841	-34,900 Reduced 17.88%	160,300 $404,000
Q2 2020 Aug 07, 2020	BUY	$2.2 - $3.71 $116,820 - $197,001	53,100 Added 37.37%	195,200 $640,000
Q4 2019 Feb 05, 2020	SELL	$3.95 - $5.35 $92,430 - $125,189	-23,400 Reduced 14.14%	142,100 $671,000
Q3 2019 Nov 07, 2019	BUY	$4.13 - $6.94 $4,956 - $8,328	1,200 Added 0.73%	165,500 $708,000
Q2 2019 Aug 09, 2019	BUY	$3.98 - $6.2 $151,240 - $235,600	38,000 Added 30.09%	164,300 $958,000
Q3 2017 Nov 06, 2017	SELL	$4.99 - $6.57 $82,285 - $108,339	-16,490 Reduced 11.55%	126,300 $775,000
Q2 2017 Aug 11, 2017	BUY	N/A	142,790	142,790 $888,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

Stay updated on New York State Common Retirement Fund with notifications on news.